Dipeptidyl peptidase IV inhibitors: A new paradigm in type 2 diabetes treatment

Current Drug Targets

Volumn 15, Issue 6, 2014, Pages 600-621

  Janardhan, Sridhara ^a   Narahari Sastry, G ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Activity and selectivity; DPP4; DPP8; DPP9; GIP; GLP 1; T2D

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL] AMINO] ETHYL] AMINO] NICOTINONITRILE; 6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ALOGLIPTIN; CARMEGLIPTIN; DENAGLIPTIN; DIGOXIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DUTOGLIPTIN; GASTRIC INHIBITORY POLYPEPTIDE; GEMIGLIPTIN; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; GOSOGLIPTIN; INCRETIN; ISOLEUCINE THIAZOLIDIDE; LC 15 0133; LINAGLIPTIN; MELOGLIPTIN; METFORMIN; PIOGLITAZONE; PLACEBO; PYRROLIDINE DERIVATIVE; SAXAGLIPTIN; SIMVASTATIN; SITAGLIPTIN; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN; XANTHINE; [5 AMINO 4 (2, 4, 5 TRIFLUOROPHENYL) 1 CYCLOHEXENYL] [5, 6 DIHYDRO 3 (TRIFLUOROMETHYL) 1, 2, 4 TRIAZOLO [4, 3 A] PYRAZIN 7 (8H) YL] METHANONE; [5 AMINO 4 (2,4,5 TRIFLUOROPHENYL) 1 CYCLOHEXENYL][5,6 DIHYDRO 3 (TRIFLUOROMETHYL) 1,2,4 TRIAZOLO[4,3 A]PYRAZIN 7(8H) YL]METHANONE; ANTIDIABETIC AGENT; ENZYME INHIBITOR;

BIOSYNTHESIS; CARDIOVASCULAR SYSTEM; CONSTIPATION; COUGHING; DIZZINESS; FIBRINOLYSIS; GENE EXPRESSION; GLUCAGON RELEASE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HEADACHE; HEMATOPOIETIC STEM CELL; HUMAN; HYDROGEN BOND; HYPOGLYCEMIA; INFLAMMATION; MOLECULAR DOCKING; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLEIOTROPY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; ENZYME ACTIVE SITE; METABOLISM; PROTEIN CONFORMATION;

ANIMALS; CATALYTIC DOMAIN; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; ENZYME INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, MOLECULAR; PROTEIN CONFORMATION;

EID: 84899882143     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666140311102638     Document Type: Review

References (173)

1. Cooke DW, Plotnick L. Type 1 diabetes mellitus in pediatrics. Pediatr Rev 2008; 29: 374-84; quiz 85.
2. Atkinson MA, Maclaren NK. The pathogenesis of insulindependent diabetes mellitus. N Engl J Med 1994; 331: 1428-36.
3. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 318-68.
4. Riserus U, Willett WC, Hu FB. Dietary fats and prevention of type 2 diabetes. Prog Lipid Res 2009; 48: 44-51.
5. Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995; 16: 390-410.
6. Leiting B, Pryor KD, Wu JK, et al. Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem J 2003; 371: 525-32.
7. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002; 122: 531-44.
8. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. Nature 1983; 304: 368-71.
9. Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993; 42: 658-61.
10. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-35.
11. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987; 79: 616-9.
12. Matsuyama T, Komatsu R, Namba M, et al. Glucagon-like peptide-1 (7-36 amide): a potent glucagonostatic and insulinotropic hormone. Diabetes Res Clin Pract 1988; 5: 281-4.
13. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 1987; 84: 3434-8.
14. Wettergren A, Schjoldager B, Mortensen PE, et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-73.
15. Li Y, Hansotia T, Yusta B, et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003; 278: 471-8.
16. Fujita Y, Wideman RD, Asadi A, et al. Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alphacells and promotes insulin secretion. Gastroenterology 2010; 138: 1966-75.
17. Buhren BA, Gasis M, Thorens B, Muller HW, Bosse F. Glucosedependent insulinotropic polypeptide (GIP) and its receptor (GIPR): cellular localization, lesion-affected expression, and impaired regenerative axonal growth. J Neurosci Res 2009; 87: 1858-70.
18. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucosedependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-96.
19. Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci 2000; 66: 91-103.
20. Bollag RJ, Zhong Q, Phillips P, et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 2000; 141: 1228-35.
21. Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8: 738-42.
22. de Meester I, Lambeir AM, Proost P, Scharpe S. Dipeptidyl peptidase IV substrates. An update on in vitro peptide hydrolysis by human DPPIV. Adv Exp Med Biol 2003; 524: 3-17.
23. Venalainen JI, Juvonen RO, Mannisto PT. Evolutionary relationships of the prolyl oligopeptidase family enzymes. Eur J Biochem 2004; 271: 2705-15.
24. Abbott CA, Yu DM, Woollatt E, et al. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 2000; 267: 6140-50.
25. Olsen C, Wagtmann N. Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV. Gene 2002; 299: 185-93.
26. Chen WT, Kelly T, Ghersi G. DPPIV, seprase, and related serine peptidases in multiple cellular functions. Curr Top Dev Biol 2003; 54: 207-32.
27. Ghersi G, Zhao Q, Salamone M, et al. The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. Cancer Res 2006; 66: 4652-61.
28. Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001; 54: 249-64.
29. De Meester I, Korom S, Van Damme J, Scharpe S. CD26, let it cut or cut it down. Immunol Today 1999; 20: 367-75.
30. Maes M, Scharpe S, De Meester I, et al. Components of biological variation in prolyl endopeptidase and dipeptidyl-peptidase IV activity in plasma of healthy subjects. Clin Chem 1994; 40: 1686-91.
31. Wilson MJ, Ruhland AR, Pryor JL, et al. Prostate specific origin of dipeptidylpeptidase IV (CD-26) in human seminal plasma. J Urol 1998; 160: 1905-9.
32. Engel M, Hoffmann T, Wagner L, et al. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci USA 2003; 100: 5063-8.
33. Tanaka T, Camerini D, Seed B, et al. Cloning and functional expression of the T cell activation antigen CD26. J Immunol 1992; 149: 481-6.
34. Janardhan S, Padmanabha Reddy Y. Homology Modeling and Molecular Docking studies of Human DPP8 and DPP9. Int J Pharm Res Dev 2011; 2: 131-46.
35. Chien CH, Huang LH, Chou CY, et al. One site mutation disrupts dimer formation in human DPP-IV proteins. J Biol Chem 2004; 279: 52338-45.
36. Thoma R, Loffler B, Stihle M, et al. Structural basis of prolinespecific exopeptidase activity as observed in human dipeptidyl peptidase-IV. Structure 2003; 11: 947-59.
37. Bjelke JR, Christensen J, Branner S, et al. Tyrosine 547 constitutes an essential part of the catalytic mechanism of dipeptidyl peptidase IV. J Biol Chem 2004; 279: 34691-7.
38. Ajami K, Abbott CA, Obradovic M, et al. Structural requirements for catalysis, expression, and dimerization in the CD26/DPIV gene family. Biochemistry (Mosc) 2003; 42: 694-701.
39. Meng W, Brigance RP, Chao HJ, et al. Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxa mides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors. J Med Chem 2010; 53: 5620-8.
40. Rasmussen HB, Branner S, Wiberg FC, Wagtmann N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol 2003; 10: 19-25.
41. Iwaki-Egawa S, Watanabe Y, Fujimoto Y. CD26/dipeptidyl peptidase IV does not work as an adenosine deaminase-binding protein in rat cells. Cell Immunol 1997; 178: 180-6.
42. Richard E, Alam SM, Arredondo-Vega FX, Patel DD, Hershfield MS. Clustered charged amino acids of human adenosine deaminase comprise a functional epitope for binding the adenosine deaminase complexing protein CD26/dipeptidyl peptidase IV. J Biol Chem 2002; 277: 19720-6.
43. Rahfeld J, Schierhorn M, Hartrodt B, Neubert K, Heins J. Are diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates of dipeptidyl peptidase IV? Biochim Biophys Acta 1991; 1076: 314-6.
44. Schechter I, Berger A. On the active site of proteases. 3. Mapping the active site of papain; specific peptide inhibitors of papain. Biochem Biophys Res Commun 1968; 32: 898-902.
45. Augustyns K, Bal G, Thonus G, et al. The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors. Curr Med Chem 1999; 6: 311-27.
46. Marguet D, Baggio L, Kobayashi T, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000; 97: 6874-9.
47. Oravecz T, Pall M, Roderiquez G, et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 1997; 186: 1865-72.
48. Proost P, Schutyser E, Menten P, et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 2001; 98: 3554-61.
49. Proost P, Struyf S, Schols D, et al. Processing by CD26/dipeptidylpeptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett 1998; 432: 73-6.
50. Sakurada C, Sakurada S, Hayashi T, et al. Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase IV: an in vitro and in vivo study. Biochem Pharmacol 2003; 66: 653-61.
51. Zhu L, Tamvakopoulos C, Xie D, et al. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J Biol Chem 2003; 278: 22418-23.
52. Brubaker PL, Izzo A, Hill M, Drucker DJ. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol 1997; 272: E1050-8.
53. Lambeir AM, Durinx C, Proost P, et al. Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. FEBS Lett 2001; 507: 327-30.
54. Nausch I, Mentlein R, Heymann E. The degradation of bioactive peptides and proteins by dipeptidyl peptidase IV from human placenta. Biol Chem Hoppe Seyler 1990; 371: 1113-8.
55. Mentlein R. Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24.
56. Mentlein R, Dahms P, Grandt D, Kruger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 1993; 49: 133-44.
57. Zhang XY, De Meester I, Lambeir AM, et al. Study of the enzymatic degradation of vasostatin I and II and their precursor chromogranin A by dipeptidyl peptidase IV using highperformance liquid chromatography/electrospray mass spectrometry. J Mass Spectrom 1999; 34: 255-63.
58. Jacotot E, Callebaut C, Blanco J, et al. Dipeptidyl-peptidase IVbeta, a novel form of cell-surface-expressed protein with dipeptidyl-peptidase IV activity. Eur J Biochem 1996; 239: 248-58.
59. Abbott CA, McCaughan GW, Gorrell MD. Two highly conserved glutamic acid residues in the predicted beta propeller domain of dipeptidyl peptidase IV are required for its enzyme activity. FEBS Lett 1999; 458: 278-84.
60. Aertgeerts K, Levin I, Shi L, et al. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J Biol Chem 2005; 280: 19441-4.
61. Strop P, Bankovich AJ, Hansen KC, Garcia KC, Brunger AT. Structure of a human A-type potassium channel interacting protein DPPX, a member of the dipeptidyl aminopeptidase family. J Mol Biol 2004; 343: 1055-65.
62. Fulop V, Bocskei Z, Polgar L. Prolyl oligopeptidase: an unusual beta-propeller domain regulates proteolysis. Cell 1998; 94: 161-70.
63. Maes MB, Dubois V, Brandt I, et al. Dipeptidyl peptidase 8/9-like activity in human leukocytes. J Leukoc Biol 2007; 81: 1252-7.
64. Ajami K, Abbott CA, McCaughan GW, Gorrell MD. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta 2004; 1679: 18-28.
65. Bjelke JR, Christensen J, Nielsen PF, et al. Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV. Biochem J 2006; 396: 391-9.
66. Wang XM, Yao TW, Nadvi NA, et al. Fibroblast activation protein and chronic liver disease. Front Biosci 2008; 13: 3168-80.
67. Park JE, Lenter MC, Zimmermann RN, et al. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 1999; 274: 36505-12.
68. Blanco J, Nguyen C, Callebaut C, et al. Dipeptidyl-peptidase IVbeta--further characterization and comparison to dipeptidylpeptidase IV activity of CD26. Eur J Biochem 1998; 256: 369-78.
69. Duke-Cohan JS, Tang W, Schlossman SF. Attractin: a cub-family protease involved in T cell-monocyte/macrophage interactions. Adv Exp Med Biol 2000; 477: 173-85.
70. Friedrich D, Hoffmann T, Bar J, et al. Does human attractin have DP4 activity? Biol Chem 2007; 388: 155-62.
71. Wrenger S, Guth B, Schultze B, et al. Expression of dipeptidyl peptidase IV-like enzymes in human peripheral blood mononuclear cells. Adv Exp Med Biol 2006; 575: 87-91.
72. Maes MB, Lambeir AM, Gilany K, et al. Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7). Biochem J 2005; 386: 315-24.
73. Maes MB, Scharpe S, De Meester I. Dipeptidyl peptidase II (DPPII), a review. Clin Chim Acta 2007; 380: 31-49.
74. Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005; 54: 2988-94.
75. Rosenblum JS, Kozarich JW. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol 2003; 7: 496-504.
76. Chourasia M, Sastry GM, Sastry GN. Aromatic-Aromatic Interactions Database, A(2)ID: an analysis of aromatic pi-networks in proteins. Int J Biol Macromol 2011; 48: 540-52.
77. Reddy AS, Amarnath HS, Bapi RS, Sastry GM, Sastry GN. Protein ligand interaction database (PLID). Comput Biol Chem 2008; 32: 387-90.
78. Reddy AS, Sastry GM, Sastry GN. Cation-aromatic database. Proteins 2007; 67: 1179-84.
79. Mahadevi AS, Sastry GN. Cation-pi interaction: its role and relevance in chemistry, biology, and material science. Chem Rev 2013; 113: 2100-38.
80. Vijay D, Sastry GN. Exploring the size dependence of cyclic and acyclic pi-systems on cation-pi binding. Phys Chem Chem Phys 2008; 10: 582-90.
81. Vijay D, Zipse H, Sastry GN. On the cooperativity of cation-pi and hydrogen bonding interactions. J Phys Chem B 2008; 112: 8863-7.
82. Delgado M, Leceta J, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression. J Immunol 1999; 163: 3629-35.
83. Itou M, Kawaguchi T, Taniguchi E, Sata M. Dipeptidyl peptidase-4: a key player in chronic liver disease. World J Gastroenterol 2013; 19: 2298-306.
84. Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008; 24: 537-50.
85. Ou X, O'Leary HA, Broxmeyer HE. Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types. Blood 2013; 122: 161-9.
86. Salgado FJ, Lojo J, Alonso-Lebrero JL, et al. A role for interleukin-12 in the regulation of T cell plasma membrane compartmentation. J Biol Chem 2003; 278: 24849-57.
87. Preller V, Gerber A, Wrenger S, et al. TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26. J Immunol 2007; 178: 4632-40.
88. Lambeir AM, Proost P, Durinx C, et al. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem 2001; 276: 29839-45.
89. Christopherson KW, 2nd, Cooper S, Broxmeyer HE. Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood 2003; 101: 4680-6.
90. Christopherson KW, 2nd, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004; 305: 1000-3.
91. Kikkawa F, Kajiyama H, Ino K, Shibata K, Mizutani S. Increased adhesion potency of ovarian carcinoma cells to mesothelial cells by overexpression of dipeptidyl peptidase IV. Int J Cancer 2003; 105: 779-83.
92. Wesley UV, Albino AP, Tiwari S, Houghton AN. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med 1999; 190: 311-22.
93. Adams S, Miller GT, Jesson MI, et al. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res 2004; 64: 5471-80.
94. Gonzalez-Gronow M, Hershfield MS, Arredondo-Vega FX, Pizzo SV. Cell surface adenosine deaminase binds and stimulates plasminogen activation on 1-LN human prostate cancer cells. J Biol Chem 2004; 279: 20993-8.
95. Shirakawa J, Fujii H, Ohnuma K, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 2011; 60: 1246-57.
96. Ospelt C, Mertens JC, Jungel A, et al. Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2010; 62: 1224-35.
97. Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005; 289: H2401-8.
98. Jackson EK, Mi Z. Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension. Hypertension 2008; 51: 1637-42.
99. Madar DJ, Kopecka H, Pireh D, et al. Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]-4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes. J Med Chem 2006; 49: 6416-20.
100. Pei Z, Li X, von Geldern TW, et al. Discovery of (4R,5S)-5-amino-4-(2,4,5-trifluorophenyl)cyclohex-1-enyl)-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2006; 49: 6439-42.
101. Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007; 50: 2297-300.
102. Mattei P, Boehringer M, Di Giorgio P, et al. Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett 2010; 20: 1109-13.
103. Gupta R, Walunj SS, Tokala RK, et al. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets 2009; 10: 71-87.
104. Yasuda N, Nagakura T, Inoue T, et al. E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-o ne tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor. Eur J Pharmacol 2006; 548: 181-7.
105. Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylme thyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem 2007; 50: 6450-3.
106. Sudre B, Broqua P, White RB, et al. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Diabetes 2002; 51: 1461-9.
107. Yoo HH, Chung HJ, Lee J, et al. Enzymatic C-demethylation of 1-[2-(5-tert-butyl-[1,3,4]oxadiazole-2-carbonyl)-4-fluoro-pyrrolidin-1-yl]-2-(2-hydroxy-1,1-dimethyl-ethyla mino)-ethanone (LC15-0133) in rat liver microsomes. Drug Metab Dispos 2008; 36: 485-9.
108. Rosenstock J, Lewin AJ, Norwood P, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes. Diabet Med 2011; 28: 464-9.
109. Takasaki K, Iwase M, Nakajima T, et al. K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent. Eur J Pharmacol 2004; 486: 335-42.
110. Sakashita H, Kitajima H, Nakamura M, Akahoshi F, Hayashi Y. 1-(S)-gamma-substituted prolyl)-(S)-2-cyanopyrrolidine as a novel series of highly potent DPP-IV inhibitors. Bioorg Med Chem Lett 2005; 15: 2441-5.
111. Thomas L, Eckhardt M, Langkopf E, et al. (R)-8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008; 325: 175-82.
112. Hughes TE, Mone MD, Russell ME, Weldon SC, Villhauer EB. NVP-DPP728 (1-[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino] acetyl]-2-cyano-(S)-pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry (Mosc) 1999; 38: 11597-603.
113. Pospisilik JA, Stafford SG, Demuth HU, et al. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 2002; 51: 943-50.
114. Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48: 5025-37.
115. Kim D, Kowalchick JE, Edmondson SD, et al. Triazolopiperazineamides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate). Bioorg Med Chem Lett 2007; 17: 3373-7.
116. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005; 7: 692-8.
117. Szczepankiewicz BG, Kurukulasuriya R. Aromatic heterocyclebased DPP-IV inhibitors: xanthines and related structural types. Curr Top Med Chem 2007; 7: 569-78.
118. Matsuyama-Yokono A, Tahara A, Nakano R, et al. ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity. Biochem Pharmacol 2008; 76: 98-107.
119. Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003; 46: 2774-89.
120. Demuth HU, McIntosh CH, Pederson RA. Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 2005; 1751: 33-44.
121. Furrer D, Kaufmann K, Tschuor F, Reusch CE, Lutz TA. The dipeptidyl peptidase IV inhibitor NVP-DPP728 reduces plasma glucagon concentration in cats. Vet J 2010; 183: 355-7.
122. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 1999; 42: 1324-31.
123. Ahren B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002; 25: 869-75.
124. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48: 141-51.
125. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194-205.
126. Tiwari A. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Curr Opin Investig Drugs 2009; 10: 1091-104.
127. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13: 65-74.
128. Dhillon S, Weber J. Saxagliptin. Drugs 2009; 69: 2103-14.
129. Wesley UV, Tiwari S, Houghton AN. Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int J Cancer 2004; 109: 855-66.
130. Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther 2009; 26: 249-62.
131. Brandt I, Joossens J, Chen X, et al. Inhibition of dipeptidylpeptidase IV catalyzed peptide truncation by Vildagliptin (2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile). Biochem Pharmacol 2005; 70: 134-43.
132. He YL, Sadler BM, Sabo R, et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 2007; 46: 787-802.
133. Ahren B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-84.
134. O'Farrell AM, van Vliet A, Abou Farha K, et al. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single-and multiple-dose studies in healthy subjects. Clin Ther 2007; 29: 1692-705.
135. Pattzi HM, Pitale S, Alpizar M, et al. Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab 2010; 12: 348-55.
136. Sanford DG, Wang p, Lai JH, Kiritsy C, Bachovchin WW. ARI2243, a Highly Potent and Selective Dipeptidyl Peptidase IV (DPP4) Inhibitor with exceptional anti-hyperglycemic activity for the Treatment of Type 2 Diabetes. Chicago American Diabetes Association 2007; Abstract: 604.
137. Kuhlmann O, Paehler A, Weick I, et al. Pharmacokinetics and metabolism of the dipeptidyl peptidase IV inhibitor carmegliptin in rats, dogs, and monkeys. Xenobiotica 2010; 40: 840-52.
138. Haffner CD, McDougald DL, Reister SM. Synthesis and biological evaluation of potent, selective, orally active 4-fluoro-2-cyanopyrrolidine inhibitors of DPP-IV. 228th ACSl Meeting, Philadelphia, USA 2004.
139. Greene RJ, Tu H, Gibbs JP, Greg Slatter J. Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222. Xenobiotica 2011; 41(11): 945-57.
140. Chyan YJ, Chuang LM. Dipeptidyl peptidase IV inhibitors: an evolving treatment for type 2 diabetes from the incretin concept. Recent Patents Endocr, Metab Immun Drug Discov 2007; 1: 15-24.
141. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287: E199-206.
142. Bunck MC, Diamant M, Corner A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009; 32: 762-8.
143. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010; 12: 648-58.
144. Hu P, Yin Q, Deckert F, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. J Clin Pharmacol 2009; 49: 39-49.
145. Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007; 30: 1862-4.
146. Parsa KV, Pal M. Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview. Expert Opin Drug Discov 2011; 6: 855-69.
147. Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010; 70: 2051-72.
148. Alogliptin (nesina) for type 2 diabetes. Med Lett Drugs Ther 2013; 55: 41-3.
149. von Eynatten M, Gong Y, Emser A, Woerle HJ. Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials. Cardiovasc Diabetol 2013; 12: 60.
150. Neumiller JJ, Setter SM. Review of linagliptin for the treatment of type 2 diabetes mellitus. Clin Ther 2012; 34: 993-1005.
151. Kang NS, Ahn JH, Kim SS, Chae CH, Yoo SE. Docking-based 3DQSAR study for selectivity of DPP4, DPP8, and DPP9 inhibitors. Bioorg Med Chem Lett 2007; 17: 3716-21.
152. Gao YD, Feng D, Sheridan RP, et al. Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors. Bioorg Med Chem Lett 2007; 17: 3877-9.
153. Agrawal R, Jain P, Dikshit SN, Jain S. 3D QSAR and Docking Studies of Various Amido and Benzyl-Substituted 3-amino-4-(2-cyanopyrrolidide)Pyrrolidinyl Analogs as DPP-IV Inhibitors. Protein Pept Lett 2013; 20(9): 1066-78.
154. Paliwal S, Seth D, Yadav D, Yadav R. Development of a robust QSAR model to predict the affinity of pyrrolidine analogs for dipeptidyl peptidase IV (DPP-IV). J Enzyme Inhib Med Chem 2011; 26: 129-40.
155. Murugesan V, Sethi N, Prabhakar YS, Katti SB. CoMFA and CoMSIA of diverse pyrrolidine analogues as dipeptidyl peptidase IV inhibitors: active site requirements. Mol Divers 2011; 15: 457-66.
156. Saqib U, Siddiqi MI. 3D-QSAR studies on triazolopiperazine amide inhibitors of dipeptidyl peptidase-IV as anti-diabetic agents. SAR QSAR Environ Res 2009; 20: 519-35.
157. Jiang YK. Molecular docking and 3D-QSAR studies on betaphenylalanine derivatives as dipeptidyl peptidase IV inhibitors. J Mol Model 2010; 16: 1239-49.
158. Sharma M, Gupta M, Singh D, Kumar M, Kaur P. Synthesis, Evaluation and Molecular Docking of Prolyl-Fluoropyrrolidine Derivatives as Dipeptidyl Peptidase IV Inhibitors. Chem Biol Drug Des 2013; 82: 156-66.
159. Zhu Y, Xia S, Zhu M, et al. Synthesis, biological assay in vitro and molecular docking studies of new imidazopyrazinone derivatives as potential dipeptidyl peptidase IV inhibitors. Eur J Med Chem 2010; 45: 4953-62.
160. Wu D, Jin F, Lu W, et al. Synthesis, structure-activity relationship, and pharmacophore modeling studies of pyrazole-3-carbohydrazone derivatives as dipeptidyl peptidase IV inhibitors. Chem Biol Drug Des 2012; 79: 897-906.
161. Al-Masri IM, Mohammad MK, Taha MO. Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening. Chem Med Chem 2008; 3: 1763-79.
162. Janardhan S, Srivani P, Sastry GN. Choline kinase: an important target for cancer. Curr Med Chem 2006; 13: 1169-86.
163. Srivastava HK, Bohari MH, Sastry GN. Modeling anti-HIV compounds: the role of analogue-based approaches. Curr Comput Aided Drug Des 2012; 8: 224-48.
164. Badrinarayan P, Sastry GN. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach. J Mol Graph Model 2012; 34: 89-100.
165. Reddy AS, Pati SP, Kumar PP, Pradeep HN, Sastry GN. Virtual screening in drug discovery--a computational perspective. Curr Protein Pept Sci 2007; 8: 329-51.
166. Murthy JN, Nagaraju M, Sastry GM, Rao AR, Sastry GN. Active site acidic residues and structural analysis of modelled human aromatase: a potential drug target for breast cancer. J Comput Aided Mol Des 2005; 19: 857-70.
167. Reddy Ch S, Vijayasarathy K, Srinivas E, Sastry GM, Sastry GN. Homology modeling of membrane proteins: a critical assessment. Comput Biol Chem 2006; 30: 120-6.
168. Janardhan S, Srivani P, Sastry GN. 2D and 3D Quantitative Structure-Activity Relationship Studies on a Series of bis-Pyridinium Compounds as Choline Kinase Inhibitors. QSAR Comb Sci 2006; 25: 860-72.
169. Janardhan S, Padmanabha Reddy Y. Molecular Modeling Studies of--aminoacyl containing Homopiperazine derivatives as DPP4 Inhibitors. Int J Drug Des Discov 2011; 2: 533-47.
170. Ravindra GK, Achaiah G, Sastry GN. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking. Eur J Med Chem 2008; 43: 830-8.
171. Bohari MH, Sastry GN. FDA approved drugs complexed to their targets: evaluating pose prediction accuracy of docking protocols. J Mol Model 2012; 18: 4263-74.
172. Badrinarayan P, Sastry GN. Rational approaches towards lead optimization of kinase inhibitors: the issue of specificity. Curr Pharm Des 2013; 19: 4714-38.
173. Srivastava HK, Sastry GN. Molecular dynamics investigation on a series of HIV protease inhibitors: assessing the performance of MM-PBSA and MM-GBSA approaches. J Chem Inf Model 2012; 52: 3088-98.